Japan's health ministry has approved five types of coronavirus vaccines for use in this season's campaign that starts on October 1.
People aged 65 or older and those between 60 and 64 years old with a high risk of developing severe COVID symptoms are eligible for the campaign.
The five types approved on Thursday include a new product called a replicon RNA vaccine that is capable of self-amplifying mRNA, or messenger RNA, which helps produce antibodies to the virus.
The others are three mRNA vaccines that have already been used in Japan and a recombinant protein vaccine.
The fee differs by municipalities. The central government will provide local governments with a per-shot subsidy of 8,300 yen, or about 58 dollars, to cap a copayment of under about 50 dollars.
People who are not eligible for the campaign will have to pay the full expense.
People aged 65 or older and those between 60 and 64 years old with a high risk of developing severe COVID symptoms are eligible for the campaign.
The five types approved on Thursday include a new product called a replicon RNA vaccine that is capable of self-amplifying mRNA, or messenger RNA, which helps produce antibodies to the virus.
The others are three mRNA vaccines that have already been used in Japan and a recombinant protein vaccine.
The fee differs by municipalities. The central government will provide local governments with a per-shot subsidy of 8,300 yen, or about 58 dollars, to cap a copayment of under about 50 dollars.
People who are not eligible for the campaign will have to pay the full expense.
Similar Readings (5 items)
4th vaccine shots expanded to medical workers, staff at facilities for elderly
Japan to provide Omicron vaccines to public starting October
Japan to start giving Omicron-targeting vaccines
Pfizer applies to use updated vaccine for younger children in Japan
Japan's first domestically produced coronavirus vaccine now available to public
Summary
Japan's health ministry has approved five COVID-19 vaccines for the upcoming campaign, starting in October. Eligible are those aged 65 or older and adults aged 60-64 with high-risk factors. These include a new replicon RNA vaccine, three mRNA vaccines already used in Japan, and a recombinant
Statistics
144
Words1
Read CountDetails
ID: 3d2b6d9f-d327-4e0b-9f3d-835281e25b24
Category ID: nhk
URL: https://www3.nhk.or.jp/nhkworld/en/news/20240920_12/
Date: Sept. 20, 2024
Created: 2024/09/21 07:00
Updated: 2025/12/08 10:25
Last Read: 2024/09/21 09:12